Cytokinetics Inc
CYTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.61B
Close$
$-13.33
120.9% downside
Current Fair Value
120.9% downsideOvervalued by 120.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.61 Billion |
|---|---|
| Enterprise Value | $9.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.54 |
| Beta | 0.36 |
| Outstanding Shares | 132,086,000 |
Return
| Return on Equity | 515.31% |
|---|---|
| Return on Assets | -46.45% |
| Return on Invested Capital | -48.69% |
Valuation & Multiples
| P/E Ratio | -8.59 |
|---|---|
| PEG | -17.93 |
| Price to Sales | - |
| Price to Book Ratio | -31.98 |
| Enterprise Value to Revenue | 135.7 |
| Enterprise Value to EBIT | -11.35 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | -7.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.63
Average shareholder expectationRevenue Estimate
$17.59 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.47
Average shareholder expectationRevenue Estimate
$36.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 16.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 122.36% |
|---|---|
| Total Invested | $22.25M▼ 99.84% |
| Investors Holding | 27▼ 487.00% |
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum